Hepion appoints Anand Reddi and Kaouthar Lbiati to Board of Directors

Hepion Pharmaceuticals, Inc.

Board expanded to 8; Reddi and Lbiati appointed independent directors effective June 27, 2022.
Each receives $50,000 annual cash retainer and option to purchase 60,000 shares of common stock.
Anand Reddi is VP at Adverum Biotechnologies; previously led international access at Gilead for HIV and hepatitis drugs.
Kaouthar Lbiati is VP at Cytovia Therapeutics; held global leadership roles at Amgen, GSK, and Sanofi.
Company is preparing rencofilstat for three Phase 2 trials in NASH and HCC and exploring partnering opportunities.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kaouthar Lbiati

independent director

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2022-06-27
Filed: June 28, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022

Appointed

Anand Reddi

independent director

HEPA · Hepion Pharmaceuticals, Inc.

Effective: 2022-06-27
Filed: June 28, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kaouthar Lbiati was elected as independent director at Hepion Pharmaceuticals, Inc..

Action: elected
Role: independent director

Exact text from the filing

the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Anand Reddi was elected as independent director at Hepion Pharmaceuticals, Inc..

Action: elected
Role: independent director

Exact text from the filing

the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022

View on SEC.gov

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-075050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.